Integragen Valuation
| ALINT Stock | EUR 0.60 0.01 1.69% |
Integragen is overvalued. Integragen retains a regular Real Value of €0.52 per share. The prevalent price of the firm is €0.6. Our model calculates the value of Integragen from evaluating the firm fundamentals such as Return On Asset of 0.0149, current valuation of 5.39 M, and Return On Equity of 0.15 as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Integragen's price fluctuation is out of control at this time. Calculation of the real value of Integragen is based on 3 months time horizon. Increasing Integragen's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Integragen's intrinsic value may or may not be the same as its current market price of 0.60, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.6 | Real 0.52 | Hype 0.6 | Naive 0.46 |
The intrinsic value of Integragen's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Integragen's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Integragen helps investors to forecast how Integragen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Integragen more accurately as focusing exclusively on Integragen's fundamentals will not take into account other important factors: Integragen Total Value Analysis
Integragen is presently projected to have takeover price of 5.39 M with market capitalization of 8.52 M, debt of 1.95 M, and cash on hands of 1.84 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Integragen fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.39 M | 8.52 M | 1.95 M | 1.84 M |
Integragen Investor Information
About 66.0% of the company shares are held by company insiders. The book value of Integragen was presently reported as 0.31. The company had not issued any dividends in recent years. Based on the analysis of Integragen's profitability, liquidity, and operating efficiency, Integragen is not in a good financial situation at the moment. It has a very high risk of going through financial straits in February.Integragen Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Integragen has an asset utilization ratio of 117.9 percent. This connotes that the Company is making €1.18 for each dollar of assets. An increasing asset utilization means that Integragen is more efficient with each dollar of assets it utilizes for everyday operations.Integragen Ownership Allocation
Integragen retains majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 65.9 (percent) of Integragen outstanding shares that are owned by insiders attests that they have been buying or selling the stock in recent months in anticipation of some upcoming event.Integragen Profitability Analysis
The company reported the revenue of 11.32 M. Net Income was 15 K with profit before overhead, payroll, taxes, and interest of 11.32 M.About Integragen Valuation
The stock valuation mechanism determines Integragen's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Integragen based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Integragen. We calculate exposure to Integragen's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Integragen's related companies.IntegraGen SA provides human genome analysis services for academic and private laboratories in France and the United States. IntegraGen SA was founded in 2000 and is headquartered in vry, France. INTEGRAGEN operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 43 people.
8 Steps to conduct Integragen's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Integragen's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Integragen's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Integragen's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Integragen's revenue streams: Identify Integragen's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Integragen's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Integragen's growth potential: Evaluate Integragen's management, business model, and growth potential.
- Determine Integragen's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Integragen's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Integragen Stock Analysis
When running Integragen's price analysis, check to measure Integragen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integragen is operating at the current time. Most of Integragen's value examination focuses on studying past and present price action to predict the probability of Integragen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integragen's price. Additionally, you may evaluate how the addition of Integragen to your portfolios can decrease your overall portfolio volatility.